A Hybrid Ligand- and Structure-Based Drug Design Invoked through Square Attention in Protein–Ligand Transformer

Abstract Computer-aided molecular design based on evaluation of protein–ligand (PL) binding affinity is important for accelerating drug discovery. A deep-learning model for natural language processing (NLP) involving an attention mechanism (i.e., Transformer) is expected to improve the PL-affinity evaluation along with clarifying amino acid residues and ligand atoms that are responsible for molecular interactions. However, the original attention (i.e., a scaled dot-product with row-wise Softmax normalization) is an adapted method for relationships between homogeneous inputs (e.g., two sentences in the translation tasks) and thus is not suitable to analyze heterogeneity found in input data such as proteins (102–103 residues) and ligands (101–102 atoms). In fact, due to the significant difference between the numbers of protein residues and ligand atoms, gaps in the scale of attention weights emerge after the normalization, which thus affects model performance. Herein, we report PLTransformer, which involves our novel attention mechanism with Softmax normalization exerting on both directions of protein residues and ligand atoms in a more equivalent manner, for correcting the imbalance by a tandem of attention blocks with swapped inputs. As a result, our PLTransformer shows competitive affinity predictive performance over a representative baseline while also providing the ability to identify binding pockets, including allosteric sites, and important ligand scaffolds and protein substructures without employing three-dimensional (3D) structures of PL complexes (i.e., a ligand-based drug design (LBDD) framework). Thus, the possible PL (residue–ligand atom) contacts provided by PLTransformer can assist us to select plausible PL binding modes obtained by docking simulations, promoting the identification of the appropriate binding mode such as to maximize the performance of PLTransformer (i.e., structure-based drug design (SBDD) framework).

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-10-08
DOI
https://doi.org/10.1021/acsomega.6c04325
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Hybrid Ligand- and Structure-Based Drug Design Invoked through Square Attention in Protein–Ligand Transformer

Yasunori Ohara, Hayato Kunugi, Yanhui Lu, Masaru Tateno
ACS Omega
Computational Drug Discovery Methods
article

A Hybrid Ligand- and Structure-Based Drug Design Invoked through Square Attention in Protein–Ligand Transformer

Yasunori Ohara, Hayato Kunugi, Yanhui Lu, Masaru Tateno
article en

Abstract

Abstract Computer-aided molecular design based on evaluation of protein–ligand (PL) binding affinity is important for accelerating drug discovery. A deep-learning model for natural language processing (NLP) involving an attention mechanism (i.e., Transformer) is expected to improve the PL-affinity evaluation along with clarifying amino acid residues and ligand atoms that are responsible for molecular interactions. However, the original attention (i.e., a scaled dot-product with row-wise Softmax normalization) is an adapted method for relationships between homogeneous inputs (e.g., two sentences in the translation tasks) and thus is not suitable to analyze heterogeneity found in input data such as proteins (102–103 residues) and ligands (101–102 atoms). In fact, due to the significant difference between the numbers of protein residues and ligand atoms, gaps in the scale of attention weights emerge after the normalization, which thus affects model performance. Herein, we report PLTransformer, which involves our novel attention mechanism with Softmax normalization exerting on both directions of protein residues and ligand atoms in a more equivalent manner, for correcting the imbalance by a tandem of attention blocks with swapped inputs. As a result, our PLTransformer shows competitive affinity predictive performance over a representative baseline while also providing the ability to identify binding pockets, including allosteric sites, and important ligand scaffolds and protein substructures without employing three-dimensional (3D) structures of PL complexes (i.e., a ligand-based drug design (LBDD) framework). Thus, the possible PL (residue–ligand atom) contacts provided by PLTransformer can assist us to select plausible PL binding modes obtained by docking simulations, promoting the identification of the appropriate binding mode such as to maximize the performance of PLTransformer (i.e., structure-based drug design (SBDD) framework).

ACS Omega
Japan Tobacco (United States) (US)
Openalex Percentile: Top 13%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.